Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Lantheus Holdings Inc (LNTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: LNTH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $128.31
1 Year Target Price $128.31
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.12% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.63B USD | Price to earnings Ratio 23.17 | 1Y Target Price 128.31 |
Price to earnings Ratio 23.17 | 1Y Target Price 128.31 | ||
Volume (30-day avg) 13 | Beta 0.1 | 52 Weeks Range 73.11 - 126.89 | Updated Date 07/14/2025 |
52 Weeks Range 73.11 - 126.89 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.55% | Operating Margin (TTM) 27.38% |
Management Effectiveness
Return on Assets (TTM) 14.39% | Return on Equity (TTM) 24.11% |
Valuation
Trailing PE 23.17 | Forward PE 11.85 | Enterprise Value 5301370325 | Price to Sales(TTM) 3.66 |
Enterprise Value 5301370325 | Price to Sales(TTM) 3.66 | ||
Enterprise Value to Revenue 3.45 | Enterprise Value to EBITDA 12.09 | Shares Outstanding 69185800 | Shares Floating 61821696 |
Shares Outstanding 69185800 | Shares Floating 61821696 | ||
Percent Insiders 2.24 | Percent Institutions 116.12 |
Upturn AI SWOT
Lantheus Holdings Inc
Company Overview
History and Background
Lantheus Holdings, Inc. was founded in 1956 and has evolved from a supplier of radiopharmaceuticals to a company focused on developing, manufacturing, and distributing diagnostic and therapeutic products.
Core Business Areas
- Precision Diagnostics: Provides imaging agents for diagnosis of cardiovascular, oncological, and other diseases. Includes DEFINITY and PYLARIFY.
- Strategic Therapeutics: Focuses on therapeutic applications, including radiotherapeutics for prostate cancer.
Leadership and Structure
The company is led by a CEO and a senior management team. The organizational structure includes departments for research and development, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- DEFINITY: A contrast agent used in echocardiography. Competitors include GE Healthcare, Bracco Diagnostics.
- PYLARIFY: A PSMA-targeted PET imaging agent for prostate cancer. Competitors include Blue Earth Diagnostics (Axumin), GE Healthcare.
- TECHNETIUM GENERATORS: Generators for the production of Technetium-99m. Competitors include Curium, NorthStar Medical Radioisotopes.
Market Dynamics
Industry Overview
The radiopharmaceutical market is growing due to advancements in medical imaging and increasing prevalence of diseases requiring accurate diagnostics and targeted therapies.
Positioning
Lantheus is a key player in the radiopharmaceutical market, with a focus on precision diagnostics and targeted therapeutics. It has a competitive advantage in its established product portfolio and distribution network.
Total Addressable Market (TAM)
The TAM for radiopharmaceuticals is estimated to be in the billions of USD, and growing. Lantheus is well-positioned to capture a significant share with its existing products and pipeline.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Strong distribution network
- Expertise in radiopharmaceuticals
- Focus on innovation
Weaknesses
- Dependence on key products
- Regulatory risks
- Competition from larger pharmaceutical companies
- Potential supply chain vulnerabilities
Opportunities
- Expansion into new therapeutic areas
- Development of novel imaging agents
- Strategic acquisitions
- Partnerships with research institutions
Threats
- Generic competition
- Changes in reimbursement policies
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- GE (GE)
- Siemens (SIE.DE)
- Curium (Private Company)
Competitive Landscape
Lantheus competes with larger pharmaceutical and medical device companies. It has a competitive advantage in its specialized focus on radiopharmaceuticals but faces challenges from competitors with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Lantheus has experienced revenue growth in recent years, driven by sales of PYLARIFY and DEFINITY.
Future Projections: Analysts project continued revenue growth, driven by increasing adoption of Lantheus' products and potential new product launches.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, investing in R&D, and pursuing strategic acquisitions.
Summary
Lantheus Holdings Inc. is a prominent player in the radiopharmaceutical market, specializing in precision diagnostics and strategic therapeutics. Its strong product portfolio and distribution network contribute to its competitive edge, while dependence on key products and regulatory risks pose challenges. The company's growth trajectory is fueled by expanding manufacturing capacity and strategic acquisitions. Lantheus needs to watch for increased competition from larger entities within the pharmaceutical and medical device market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports, analyst reports, industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantheus Holdings Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2015-06-25 | CEO & Director Mr. Brian A. Markison | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 808 | Website https://www.lantheus.com |
Full time employees 808 | Website https://www.lantheus.com | ||
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.